Introduction: The NLR family pyrin domain–containing 3 (NLRP3) inflammasome is a central driver of neuroinflammation and demyelination in multiple sclerosis (MS). MCC950, a selective small-molecule NLRP3 inhibitor, has emerged as a promising therapeutic candidate for MS by suppressing inflammasome formation and downstream cytokine release. Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science using the keywords “NLRP3 inflammasome,” “MCC950,” “multiple sclerosis,” “experimental autoimmune encephalomyelitis,” and “neuroinflammation.” Articles published up to 2025, including in vivo and preclinical studies, were evaluated to assess the mechanistic and therapeutic potential of MCC950 in MS Results: Evidence from experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination models demonstrates that MCC950 suppresses NLRP3–ASC–caspase-1 oligomerization, reduces IL-1β/IL-18 release, and inhibits microglial and astrocytic activation. Treatment preserves oligodendrocyte integrity, mitigates axonal loss, and maintains synaptic function. Delivery systems such as PEGylated nanoparticles enhance MCC950’s bioavailability. Discussion: MCC950 administration has been represented as a novel therapeutic strategy due to its targeted selectivity and is currently under further discovery in various combination therapies, which show synergistic efficacy with agents such as rapamycin, metformin, and Anakinra, expanding its therapeutic spectrum. Conclusion: Altogether, MCC950 represents a potent inhibitor of NLRP3 inflammasome activity with dual anti-inflammatory and neuroprotective effects in preclinical MS models. Future research should focus on optimizing pharmacokinetics, clarifying off-target interactions, and validating clinical efficacy to translate these findings into patient-centered therapies.
Rabiei et al. (Mon,) studied this question.